| 1. |
|
|
| 2. |
- Oinonen, M., et al.
(author)
-
Non-analog beta decay of Rb-74
- 2001
-
In: Physics Letters, Section B: Nuclear, Elementary Particle and High-Energy Physics. - 0370-2693. ; 511:2-4, s. 145-150
-
Journal article (peer-reviewed)abstract
- The magnitude of the Coulomb mixing parameter delta (l)(IM) has been experimentally deduced, for the first time, for the B decay of Rb-74. Th, estimated magnitude is derived from the feeding of the non-analog first excited 0(+) state in Kr-74. The inferred upper Limit of 0.07% is small compared to theoretical predictions. The half-life was measured to be 64.90(9) ms.
|
|
| 3. |
- Mann, D. L., et al.
(author)
-
Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)
- 2004
-
In: Circulation. - 1524-4539. ; 109:13, s. 1594-602
-
Journal article (peer-reviewed)abstract
- BACKGROUND: Studies in experimental models and preliminary clinical experience suggested a possible therapeutic role for the soluble tumor necrosis factor antagonist etanercept in heart failure. METHODS AND RESULTS: Patients with New York Heart Association class II to IV chronic heart failure and a left ventricular ejection fraction < or =0.30 were enrolled in 2 clinical trials that differed only in the doses of etanercept used. In RECOVER, patients received placebo (n=373) or subcutaneous etanercept in doses of 25 mg every week (n=375) or 25 mg twice per week (n=375). In RENAISSANCE, patients received placebo (n=309), etanercept 25 mg twice per week (n=308), or etanercept 25 mg 3 times per week (n=308). The primary end point of each individual trial was clinical status at 24 weeks. Analysis of the effect of the 2 higher doses of etanercept on the combined outcome of death or hospitalization due to chronic heart failure from the 2 studies was also planned (RENEWAL). On the basis of prespecified stopping rules, both trials were terminated prematurely owing to lack of benefit. Etanercept had no effect on clinical status in RENAISSANCE (P=0.17) or RECOVER (P=0.34) and had no effect on the death or chronic heart failure hospitalization end point in RENEWAL (etanercept to placebo relative risk=1.1, 95% CI 0.91 to 1.33, P=0.33). CONCLUSIONS: The results of RENEWAL rule out a clinically relevant benefit of etanercept on the rate of death or hospitalization due to chronic heart failure.
|
|
| 4. |
- Van De Vel, K., et al.
(author)
-
In-beam gamma-ray spectroscopy of Po-190 : First observation of a low-lying prolate band in Po isotopes
- 2003
-
In: European Physical Journal A. - : Springer Science and Business Media LLC. - 1434-6001 .- 1434-601X. ; 17:2, s. 167-171
-
Journal article (peer-reviewed)abstract
- Gamma rays from excited states of Po-190 have been observed using I the Jurosphere Ge-detector array coupled to the RITU gas-filled separator. They were associated with a collective band which from spin 4h onwards resembles the prolate rotational bands known in the isotones Pb-188 and Hg-186. This indicates that in Po-190 the prolate configuration becomes yrast above I = 2h. The experimental results are interpreted in a two-band mixing calculation and are in agreement with a-decay data and potential energy surface calculations.
|
|
| 5. |
- Cowie, MR, et al.
(author)
-
Clinical applications of B-type natriuretic peptide (BNP) testing
- 2003
-
In: European Heart Journal. - 0195-668X .- 1522-9645. ; 24:19, s. 1710-1718
-
Journal article (peer-reviewed)abstract
- Many claims have been made in recent years regarding the utility of plasma B-type natriuretic peptide (BNP) concentration measurements in the diagnosis, risk stratification and monitoring of patients with heart failure. This paper summarizes the current evidence and provides guidance for practising clinicians. Overall, plasma BNP testing appears to be of most value in the diagnostic arena, where it is likely to improve the performance of non-specialist physicians in diagnosing heart failure. In clinical practice, BNP testing is best used as a 'rule out' test for suspected cases of new heart failure in breathless patients presenting to either the outpatient or emergency care settings, it is not a replacement for echocardiography and full cardiological assessment, which will be required for patients with an elevated BNP concentration. Although work is ongoing in establishing the 'normal' values of BNP, heart failure appears to be highly unlikely below a plasma concentration of 100 pg/ml. However, as BNP levels rise with age and are affected by gender, comorbidity and drug therapy, the plasma BNP measurement should not be used in isolation from the clinical context.
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
- Nieminen, P., et al.
(author)
-
gamma-ray spectroscopy of Bi-191,Bi-193
- 2004
-
In: Physical Review C. Nuclear Physics. - 0556-2813 .- 1089-490X. ; 69:6, s. 064326-
-
Journal article (peer-reviewed)abstract
- Prompt and delayed gamma rays from Bi-191,Bi-193 have been identified using the recoil-decay tagging, isomer tagging, and recoil gating techniques, resulting in extensive level schemes for both nuclei. Excitation energies of the isomeric 13/2(+) states have been established and oblate strongly coupled bands built on them have been observed. The nearly spherical 9/2(-) ground-state bands appear to be crossed by more oblate-deformed low-lying structures. The properties of the bands feeding the 1/2(+) intruder states indicate some structural change between Bi-193 and Bi-191. The deformation associated with each of these states has been extracted from total Routhian surface calculations which also reveal the development of prolate minima with decreasing neutron number. B(M1)/B(E2) ratios have been measured for the observed strongly coupled bands in order to resolve the intrinsic excitations. The observed quasiparticle structures in Bi-193 and high-spin isomers both in Bi-193 and Bi-191 are interpreted based on the coupling of the odd proton to the even-even Pb core.
|
|
| 9. |
- Andreyev, A. N., et al.
(author)
-
In-beam and alpha-decay spectroscopy of Po-191 and evidence for triple shape coexistence at low energy in the daughter nucleus Pb-187
- 2002
-
In: Physical Review C. Nuclear Physics. - 0556-2813 .- 1089-490X. ; 66:1
-
Journal article (peer-reviewed)abstract
- Prompt gamma rays have been observed for the first time from the neutron-deficient nucleus Po-191 using the recoil-decay tagging technique at the RITU gas-filled separator. In addition improved alpha decay data have been measured for Po-191 and its daughter product Pb-187. The complementary gamma- and alpha-decay data point to the onset of oblate deformation in the light odd-mass Po nuclei by approaching the neutron midshell at N=104. The pattern of the favored and unfavored states observed on top of the 13/2(+) isomer in Po-191 indicates a change from the weak-coupling towards the strong-coupling scheme in Po-191m. In the daughter nucleus Pb-187, the 13/2(+) and 3/2(-) isomeric states become degenerate within the experimental accuracy. Evidence for triple shape coexistence at low energy has been found in the high-spin isomer in Pb-187. The results are supported by potential-energy surface calculations and by particle-plus-rotor calculations.
|
|
| 10. |
|
|
